Sterile Compounding Batch for Hospice with an Overlong Beyond-Use Date
A Hawaii community pharmacy operates a sterile compounding area with an ISO Class 5 laminar airflow hood inside an ISO Class 7 buffer room. The pharmacist prepares a batch of preservative-free morphine sulfate 1 mg/mL syringes for a local hospice. The pharmacy plans to assign a 30-day beyond-use date at controlled room temperature, relying on the 2008 USP <797> low-risk category. The pharmacy has not performed gloved fingertip sampling or a media fill in the past 14 months. The Hawaii Board of Pharmacy inspector arrives and asks for the compounding records, the assigned BUD rationale, and personnel validation. The pharmacist-in-charge must respond and decide whether to release the batch. The pharmacy is licensed in Hawaii and holds a sterile compounding permit. The hospice needs the syringes tomorrow.
1. Is the proposed 30-day room-temperature BUD supportable under current USP <797>? Explain.
Read the worked answer
No. The proposed BUD is not supportable under either the 2008 or the current USP <797> framework.
- Under the 2008 low-risk category, the maximum room-temperature BUD was 48 hours, not 30 days; refrigerated was 14 days and frozen was 45 days.
- Under the current USP <797> (2023), a Category 1 compounded sterile preparation may receive a BUD of up to 12 days at controlled room temperature, 30 days refrigerated, or 45 days frozen. Category 2 and Category 3 preparations have shorter limits.
A 30-day room-temperature BUD would therefore exceed the allowed limit and would misrepresent the stability and contamination risk of the preparation. The pharmacist-in-charge must assign a BUD based on the correct risk category, the starting components, the container, and the storage conditions, and must document the rationale. The batch should not be released with the proposed 30-day room-temperature dating.
2. What validation and documentation deficiencies exist, and what should the pharmacist-in-charge do before releasing the batch?
Read the worked answer
The pharmacy has not performed gloved fingertip sampling or a media fill in 14 months. USP <797> requires initial validation of personnel and, at minimum, annual revalidation of gloved fingertip sampling and media fill for personnel who compound sterile preparations. The 14-month gap is a deficiency. The inspector will also expect environmental monitoring records, cleaning and disinfection logs, training records, standard operating procedures, and a documented BUD rationale.
Before releasing the batch, the pharmacist-in-charge should quarantine it, complete the required personnel validation, review environmental monitoring, and assign a compliant BUD. If validation cannot be completed before the hospice need arises, the pharmacy should not release the batch as a sterile compounded preparation; it should arrange an alternative supply. The pharmacist-in-charge should document the corrective action and retain records for the inspector.
3. What Hawaii-specific regulatory authority does the inspector have if deficiencies are not corrected?
Read the worked answer
Hawaii’s Board of Pharmacy rules incorporate sterile compounding standards, including USP <797>, as a condition of the pharmacy’s sterile compounding permit and license. If deficiencies are not corrected, the Board may issue a notice of violation, require a plan of correction, impose fines, restrict or suspend sterile compounding, or take action against the pharmacy license or the pharmacist-in-charge. The inspector may also require the pharmacy to stop releasing affected preparations until the deficiencies are resolved. The pharmacist-in-charge should cooperate, provide the requested records, and correct the deficiencies rather than release a batch that does not meet the applicable standard.